Brief Summary
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Intervention / Treatment
- Drug: AZD2287
- Drug: AZD2275
- Drug: AZD2284
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Histologically confirmed diagnosis of adenocarcinomacancer arising from mucus-producing glands in organs of the prostate or neuroendocrine differentiated prostate cancer.
- Must have had prior bilateral orchiectomyremoval of one or both testicles, also known as orchidectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L).
- At least one metastatic lesion present on baseline Computed Tomography (CT), Magnetic Resonance Imaging (MRI), or bone scana type of medical imaging that uses a radioactive tracer to detect bone conditions or abnormalities obtained ≤ 28 days prior to the first dose of Investigational Medicinal Product (IMP). Participants may have non-measurable lesions including bone only metastases.
- Adequate organ function